ABS Laboratories is a leading authority on the quantification of nicotine, cotinine, 3-hydroxy cotinine, nitrosamines, acrolein and 3-hydroxypropylmercapturic acid (3-HPMA) (all smoking related analytes) in saliva, plasma and urine.
It has set up and validated a multitude of assays to support smoking research and the development of nicotine replacement products including the use of E-cigarettes.
The sensitive robust methods can determine nicotine and its metabolites cotinine and 3-hydroxy cotinine. The ratio of 3-hydroxy cotinine to cotinine indicates how quickly an individual metabolises nicotine so can aid in the selection of the most appropriate medication to aid smoking cessation.
It's anabasine assays used in conjunction with the cotinine and 3-hydroxy cotinine assays shows how nicotine was consumed whether it was from tobacco or a nicotine replacement therapy.
Assays for the known carcinogens, nitrosamines and acrolein found in tobacco smoke, plus acrolein’s metabolite 3-HPMA have also been used to test the effective ness of nicotine replacement therapies.
All these assays are sensitive enough to be used to investigate the effects of passive smoking and are used routinely in health surveys.
A literature search for any one of the following names provides a good insight into the scope of work that ABS Laboratories has supported in this field: C. Feyerabend, M. A. H. Russell, M. Jarvis & R. West.
Services offered include:
For any queries on the scope of the services provided please contact the business development team through the Quick Quotation link.